BNR
Burning Rock Biotech Limited
There isn't enough reported data to score BNR yet.
BNR Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Unavailable |
BNR's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
BNR PE Valuation
BNR has no meaningful PE right now: it lost money over the past year.
BNR Forward outlook
There aren't enough analyst estimates for BNR to show an outlook.
BNR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$9.65 | +$10.58 |
| Q1 2026 | -$8.45 | +$26.23 |
| Q4 2025 | -$7.77 | +$42.82 |
| Q3 2025 | -$17.38 | +$45.17 |
| Q2 2025 | -$20.23 | +$62.79 |
| Q1 2025 | -$34.68 | +$51.76 |
| Q4 2024 | -$50.59 | +$45.22 |
| Q3 2024 | -$62.55 | +$41.18 |
BNR is still losing money, but far less than before: $9.65 per share over the past year, against $216.37 at its worst in early 2020.
BNR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $20.2M | -9.2% |
| Q1 2026 | $16.2M | -19% |
| Q4 2025 | $19M | +0.2% |
| Q3 2025 | $19.8M | +2.3% |
| Q2 2025 | $22.3M | +9.6% |
| Q1 2025 | $20M | +5.9% |
| Q4 2024 | $18.9M | +4.1% |
| Q3 2024 | $19.3M | +0.8% |
BNR's revenue is shrinking: $20M last quarter, down 9.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -13% | -5.6 points |
| Q1 2026 | -17% | -6.1 points |
| Q4 2025 | -9.5% | +56 points |
| Q3 2025 | -12% | +18 points |
| Q2 2025 | -7.7% | +74 points |
| Q1 2025 | -11% | +89 points |
| Q4 2024 | -65% | +72 points |
| Q3 2024 | -30% | +110 points |
BNR's operating margin was −13% last quarter, down 5.6 points from the same quarter a year ago.
BNR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.4M | +$3.3M |
| Q1 2026 | -$4.4M | -$867K |
| Q4 2025 | $2.7M | +30% |
| Q3 2025 | $2.5M | +$7M |
| Q2 2025 | -$6.7M | -$527.2K |
| Q1 2025 | -$3.5M | +$2.5M |
| Q4 2024 | $2M | +$5.7M |
| Q3 2024 | -$4.5M | +$2.6M |
BNR has burned cash in almost every quarter: −$3M over the past year, against −$13M the year before.
BNR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.2% | +34.1K shares |
| 1 year | +0.9% | +9.2K shares |
| 3 years | +6% | +61.3K shares |
| 5 years | +4.3% | +45.2K shares |
| Available history | +369% | +854K shares |
BNR has 1M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $10,805 |
| Q3 2024 | — |
BNR hasn't bought back shares in the past year.
BNR Net Leverage
BNR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BNR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.4 | Neutral |
| Stochastic | 34.9 | Neutral |
BNR's weekly RSI is 50 (neutral) and its Stochastic is 35 (neutral).
BNR PE vs Healthcare Sector
BNR has no meaningful PE right now: it lost money over the past year.
BNR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.1 | 5.4% below |
| 20 week MA | $11.9 | 12% above |
| 50 week MA | $16.7 | 20% below |
| 100 week MA | $11.7 | 14% above |
| 200 week MA | $12.5 | 6.9% above |
BNR's trend is mixed: it's above three of its five weekly moving averages, and 6.9% above its 200-week average.
BNR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $246.3 | $257.5 | +4.5% |
| 2021 | $257.5 | $105.0 | -59% |
| 2022 | $105.0 | $20.8 | -80% |
| 2023 | $20.8 | $9.30 | -55% |
| 2024 | $9.30 | $7.14 | -23% |
| 2025 | $7.14 | $21.2 | +197% |
| 2026 YTD | $21.2 | $13.3 | -37% |
BNR's yearly returns have swung widely, from +197% in 2025 to −80% in 2022. It's down 37% so far in 2026.